Literature DB >> 2457431

Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites.

L Elias1, H A Crissman.   

Abstract

In order to gain insight into the mechanisms affecting combination treatment of tumor cells with interferon and halogenated pyrimidine antimetabolites, in vitro studies of murine colon adenocarcinoma 38 and HL-60 cell lines were undertaken. Interferons exhibited modest antiproliferative effects against these lines with DNA synthesis inhibited greater than RNA greater than protein synthesis, as studied by 3H-precursor incorporation. The adenocarcinoma cell line was considerably more sensitive to recombinant gamma-than to purified alpha/beta-interferon, while HL-60 was slightly more sensitive, in short term studies, to antiproliferative effects of recombinant alpha- than to gamma-interferon. Interferon treatment was further associated with suppression of a hyperdiploid component of the adenocarcinoma cell line, as detected by flow cytometry. Combination treatment of the adenocarcinoma cell line with interferon and halogenated pyrimidines, under 4-day continuous exposure conditions, revealed significant synergy for growth inhibition with gamma- much greater than alpha/beta-interferon and with 5-fluorodeoxyuridine greater than 5-fluorouracil much greater than 5-fluorouridine. Thus, synergy was much greater with the more antiproliferative interferon and with the antimetabolite derivative most likely to lead to thymidylate synthetase inhibition rather than RNA incorporation. Sequential 2-day + 2-day treatment revealed greater synergy when interferon preceded 5-fluorouracil or 5-fluorodeoxyuridine rather than the reverse protocol. The synergy of gamma-interferon and 5-fluorodeoxyuridine could be blocked by thymidine, which bypasses inhibition of thymidylate synthetase. HL-60 also exhibited thymidine antagonized synergistic growth-inhibitory effects of interferon and 5-fluorouracil. Analysis of this interaction by [3H]thymidine incorporation, which can reflect thymidylate synthase inhibition, revealed exaggerated responses of interferon-treated cells to either 5-fluorouracil or 5-fluorodeoxyuridine. These results indicate that interferon-halogenated pyrimidine antimetabolite synergistic interactions may be common to several cell types. Evidence is further presented for a mechanism of synergy entailing enhanced thymidylate synthetase inhibition by the antimetabolite of interferon-treated cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457431

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

Review 2.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

3.  Recombinant human interferons alpha, beta and gamma reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells.

Authors:  H R Maurer; H T Hassan; C Tsiriyotis; D A Spandidos
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 4.  Interaction of alpha-interferon with chemotherapeutic agents: effects on cytotoxic drug metabolism and multiple drug resistance.

Authors:  G J Sewell
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

5.  Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer.

Authors:  J Clark; W Sikov; F Cummings; M Browne; W Akerley; H Wanebo; A Weitberg; T Kennedy; B Cole; J Bigley; J Beitz; J Darnowski
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine.

Authors:  H Eda; K Fujimoto; S Watanabe; M Ura; A Hino; Y Tanaka; K Wada; H Ishitsuka
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Combination of interferons and cytostatic drugs for treatment of advanced colorectal cancer.

Authors:  H O Klein; G Golbach; P Voigt; C Coerper; C Bernhardt
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

8.  Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck.

Authors:  M H Huber; M Shirinian; S M Lippman; I W Dimery; R A Frankenthaler; W K Hong
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

9.  Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.

Authors:  C J Punt; P H de Mulder; J T Burghouts; D J Wagener
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.

Authors:  G G Steger; R M Mader; M P Djavanmard; M F Gnant; G Locker; C Marosi; H Rainer; R Jakesz
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.